Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab
This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for neoadjuvant treatment in resectable gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No.: LBA73). The mid-term analysis showed a clinically and statistically significant improvement in the pathological complete response (pCR) rate, making MATTERHORN the first neoadjuvant Phase III immunotherapy regimen in gastric cancer to show positive results. "Tumor Outlook" invited Professor Liang Han from Tianjin Medical University Cancer Hospital to provide an in-depth interpretation of the study.